Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 19 - Hybrid peptides
Patents for C07K 19 - Hybrid peptides (29,428)
11/2010
11/17/2010EP1830872B1 Fusion proteins
11/17/2010CN101889091A Nanocarrier based plant transfection and transduction
11/17/2010CN101886068A Immobilized SUMO system and immobilized SUMO removal system
11/17/2010CN101885778A HPV (Human Papilloma Virus) 16 type L2N120E7E6 fusion protein, gene, preparation method and application
11/17/2010CN101885777A Application of Pontin 52 as SUMO (Small Ubiquitin-related Modifier) substrate protein, SUMO Pontin 52 protein and application thereof
11/17/2010CN101885770A Fully human antibody capable of specifically bonding CD15 and use thereof
11/17/2010CN101885769A Fully human antibody capable of specifically bonding CD4 and use thereof
11/17/2010CN101311192B Process for high-efficiency expressing sTNFR/Fc fusion protein in yeast and uses thereof
11/17/2010CN101225113B Thymosin alpha1-thymopentin fusion peptide and preparation method thereof
11/16/2010US7834237 Membrane-localisable fusion protein of an aggregating portion induced through conformational polymerisation
11/16/2010US7834165 Nucleic acid sequence and vectors encoding chimeric human T1R3 taste receptor
11/16/2010US7834158 Mutated immunoglobulin-binding protein
11/16/2010US7833532 synthetic molecules comprising co-linear T-helper and CTL epitopes; enhanced ability to activate a T cell response to a CD8+ T cell epitope to induce cell mediated immunity against an invading pathogen or tumour cell
11/16/2010US7833521 Admnistering a fusion protein of interferon and albumin or an albumin variant, having a higher plasma stability than unfused interferon; albumin or variant is located either at the N-terminus or C-terminus of the fusion protein, fusion protein retains the therapeutic activity of unfused interferon
11/16/2010CA2422622C Novel baff-r nucleic acids and polypeptides
11/16/2010CA2311648C Ifnar2/ifn complex
11/15/2010CA2704505A1 Method and system for protein purification
11/15/2010CA2678775A1 Protein markers useful to differentiate immunized and infected specimens
11/11/2010WO2010129853A2 TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
11/11/2010WO2010128142A1 Method for purifying albumin
11/11/2010US20100286367 Conjugates of soluble peptidic compounds with membrane-binding agents
11/11/2010US20100286060 Specific binding agents of human angiopoeitin-2
11/11/2010US20100285591 Cyclin d polynucleotides, polypeptides and uses thereof
11/11/2010US20100285131 Fgf21 mutants and uses thereof
11/11/2010US20100285029 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies
11/11/2010US20100285014 Immunoglobulin fusion proteins
11/10/2010EP2248900A1 Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
11/10/2010EP2248828A1 Method for treating inflammation
11/10/2010EP1030867B1 Mammalian milk growth factor
11/10/2010CN1775946B Enhanced virus-mediated DNA transfer
11/10/2010CN101880328A Th multi-epitope gene and fusion protein of cryptosporidium parvum and application thereof
11/10/2010CN101880327A Scorpion arialgesic anti-tumoral peptide fusion and acquisition method thereof
11/10/2010CN101319011B Multi-type HCV-E1 epitope complex immunogen, encoding gene and application thereof
11/09/2010US7829672 Modulation of sodium channels in dorsal root ganglia
11/09/2010US7829526 DNA encoding peptide, an antibody against the peptide; cardioinhibitory, hypotensive agent; peptide as an active ingredient; marker protein, peptide tag
11/09/2010US7829092 Recombinant anti-VLA4 antibody molecules
11/09/2010CA2386242C Tumour-specific vector for gene therapy
11/04/2010WO2010126319A2 Lipopeptide with specific affinity to the fc region of an antibody, and antigen-recognizing lipid nanoparticle comprising same
11/04/2010WO2010126180A1 Creatine kinase fusion protein, preparation method thereof, and use thereof
11/04/2010WO2010124361A1 Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
11/04/2010WO2010071769A3 Chimeric l. monocytogens in1b protein
11/04/2010US20100280229 Polypeptide
11/04/2010US20100279942 Methods for treating motor neuron disease
11/04/2010US20100279928 Sldlr in viral hepatitis
11/04/2010US20100279927 Growth factor complex
11/04/2010US20100278827 Concatameric immunoadhesion molecule
11/04/2010CA2768045A1 Sensor for protein-type electron mediator
11/03/2010EP2245160A1 Cell surface display of proteins
11/03/2010EP2245051A1 Fusion polypeptides comprising a shbg dimerization component and uses thereof
11/03/2010EP1268760B1 Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments
11/03/2010EP1076662B1 Polyepitope carrier protein
11/03/2010EP0912734B1 Chimeric heteromultimer adhesins
11/03/2010CN101875700A Method for improving bioactivity of exendin fusion protein
11/03/2010CN101875699A Fusion protein of human epidermal growth factor and metallothionein and preparation method and application thereof
11/03/2010CN101875698A Long-acting polymer drug technique in protein engineering
11/03/2010CN101875688A Folic acid modification step of method for preparing recombinant tumor specific apoptosis factor and application of products of recombinant tumor specific apoptosis factor
11/03/2010CN101874898A General trivalent gene recombination vaccine for preventing infection of leptospira interrogans of different sero-groups and preparation method thereof
11/03/2010CN100999553B HR2 analogous protein and its coding gene and application
11/02/2010US7824850 Methods of protein destabilization and uses thereof
11/02/2010US7824695 recombinant proteins comprise cell recognition moiety that binds alpha 2 macroglobulin receptor, and bioactive moiety (pseudomonas exotoxin), which mediates systemic effect, does not function as immunogen and does not have ADP ribosylating activity
11/02/2010US7824683 Methods for augmenting an immune response using anti-CD40 antibodies
11/02/2010CA2181394C Ctla4 mutant molecules and uses thereof
10/2010
10/28/2010WO2010124296A2 Compositions containing hc•ha complex and methods of use thereof
10/28/2010WO2010123290A2 In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
10/28/2010WO2010123013A1 Tag peptide having protease recognition sequence and utilization of same
10/28/2010WO2010122181A1 Oligomeric proteins and the uses thereof
10/28/2010WO2010122090A1 Fgfr1c antibody combinations
10/28/2010WO2010121618A1 A tuberculosis tb vaccine to prevent reactivation
10/28/2010WO2010042751A3 Chimeric therapeutics, compositions, and methods for using same
10/28/2010WO2010042749A3 Chimeric therapeutics, compositions, and methods for using same
10/28/2010WO2010042743A3 Chimeric multiplexes, compositions, and methods for using same
10/28/2010US20100272746 Lipoparticle comprising a protein and methods of making and using the same
10/28/2010US20100272719 Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
10/28/2010CA2759583A1 A tuberculosis tb vaccine to prevent reactivation
10/28/2010CA2758842A1 Fgfr1c antibody combinations
10/28/2010CA2758571A1 Compositions containing hc-ha complex and methods of use thereof
10/28/2010CA2758445A1 In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
10/27/2010EP2242770A2 Barb4 target which comprises tata-binding protein-associated factor 15, antibody designated barb4, barb4 related antibodies, and methods of making and using same
10/27/2010EP2073850B1 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
10/27/2010EP1692160B1 Fgf-5 binding and supported peptides
10/27/2010EP1487877B1 Compositions and methods for the diagnosis of tumors
10/27/2010EP1218509B9 Fibroblast growth factor-like polypeptides
10/27/2010CN101870735A Novel high-glycosylation erythropoietin immune fusion protein
10/27/2010CN101870734A Fusogenic polypeptide for inhibiting neovascularization and coding gene and application thereof
10/27/2010CN101870733A Poultry IL-2 and newcastle disease virus HN gene recombination fusion protein and application thereof
10/26/2010US7820786 Synthetic peptides and uses therefore
10/26/2010US7820410 Proteins with high immunoreactivity and method for their production
10/26/2010US7820379 Process for high throughput screening of CpG-based immuno-agonist/antagonist
10/26/2010CA2443840C Cripto blocking antibodies and uses thereof
10/26/2010CA2326501C Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
10/26/2010CA2319211C Recombinant proteins derived from hgf and msp
10/21/2010WO2010120561A1 Anti-fcrh5 antibodies and immunoconjugates and methods of use
10/21/2010WO2010120509A2 Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
10/21/2010WO2010119693A1 Method of screening for insulin secretion-potentiating agents
10/21/2010WO2010119249A1 Therapeutic antennapedia-antibody molecules and methods of use thereof
10/21/2010WO2010065815A3 Mini-hepcidin peptides and methods of using thereof
10/21/2010WO2010046783A3 A1 moiety of cholera toxin a subunit as an adjuvant for mucosal and systemic vaccines
10/21/2010US20100269184 Apo-2DcR
10/21/2010US20100267936 PROCESS FOR CORRECTION OF A DISULFIDE MISFOLD IN Fc MOLECULES
10/21/2010US20100267931 Heterologous expression of neisserial proteins
1 ... 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 ... 295